Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

The potential of exploitation of miRNA as diagnostic agents and therapeutic tools will likely only be realized when a complete knowledge of their biology is revealed. Despite more than a decade of research, the use of miRNA as diagnostic and therapeutic tools remains a 'work in progress'. The objective of this review is to explore more recent developments in the role of deregulated miRNAs in hepatocellular carcinoma (HCC). This includes emerging insights involving miRNA biogenesis, their deregulation by cancer and their role in deregulating the principal HCC cancer pathways. Specific attention is directed at the role of deregulated miRNAs in HCC in a developing country context with high hepatitis B/C burden, as well as an examination of the challenges that confront the use of extracellular miRNAs as commercially viable diagnostic tools to detect early stage HCC.

Original publication

DOI

10.2741/4668

Type

Journal

Frontiers in bioscience (Landmark edition)

Publication Date

03/2018

Volume

23

Pages

1701 - 1720

Addresses

Department of Public Health Medicine, School of Nursing and Public Health, University of KwaZulu-Natal, Durban, South Africa, Kurt.Sartorius@wits.ac.za.

Keywords

Humans, Carcinoma, Hepatocellular, Liver Neoplasms, MicroRNAs, RNA, Messenger, Sensitivity and Specificity, Signal Transduction, Gene Expression Regulation, Neoplastic, Biomarkers, Tumor